Posted by Michael Wonder on 02 Feb 2021
Precision medicine helping to change the prognosis of a rare subtype of bowel cancer
2 February 2021 - Australians with a specific type of bowel cancer are no longer subject to a ‘one-size fits all’ treatment approach, with immuno-oncology therapy Keytruda now available as a treatment option.
MSD announced today that its cancer treatment Keytruda has been listed for use on the Australian Register of Therapeutic Goods for the first-line treatment of patients with unresectable or metastatic colorectal cancer that have a specific alteration called microsatellite instability-high or mismatch repair deficient, as determined by a validated test.
